DOCTOR ANTONIO BUZAID

Dr. Antonio C Buzaid graduated from the University of São Paulo, where he received the
Rockefeller Foundation Award for Best Student in Basic Chairs. He completed a Fellowship in
Hematology and Oncology at the University of Arizona and he was awarded the Eleanor B
Connel Award for Best Fellowship. Shortly after, he was an Assistant Professor at Yale
University and their Medical Director of the Melanoma Center and Co-Director of the Lung
Cancer Center for 4 years. He was also an Associate Professor at MD Anderson Cancer Center
and Medical Director of the Multidisciplinary Center for Melanoma and Skin Cancer for 5 years.
At MDACC, he was given the Teacher of the Year Award. Together with Dr. Raul Cutait and
Frederico Costa, he created the Oncology Center of the Syrian-Lebanese Hospital in 1998. From
then until 2010, he was Director of the Oncology Center of the Syrian-Lebanese Hospital. In
2011 he became General Medical Director of the Antonio Ermírio de Moraes Oncology Center
of Portuguese Beneficence of São Paulo. In 2015, he became a Member of the Managing
Committee of the Dayan-Daycoval Oncology Center of the Israeli Hospital Albert Einstein.


DOCTOR RENIER BRENTJENS

With a PhD in microbiology from SUNY Buffalo, Dr. Renier Brentjens is an associate member of the Memorial Sloan Kettering Cancer Center (MSKCC) and an assistant physician for their leukemia services. He initiated preclinical studies demonstrating the potential clinical application of genetically modified T cells to target the CD19 antigen by retroviral transfer of genes from artificial T cell receptors, the famous chimeric antigen (CAR) receptors. Dr. Brentjens has successfully applied these studies into the clinical setting by treating patients with chronic lymphocytic leukemia (CLL) and acute B-cell lymphoblastic leukemia (B-ALL). His current pre- clinical research in progress is focused on the development of CAR-modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “CAR armored T cells.” The work at Dr. Brentjens’ laboratory expanded this CAR technology to target additional tumor antigens expressed in other tumors, including the MUC-16 antigen target expressed in ovarian carcinomas, as well as the more ubiquitous WT-1 tumor associated antigen. These latter projects are also in the process of being transitioned into the clinical environment.


DOCTOR RAFAELA QUEIROZ

Dr. Rafaela Queiroz Caixeta holds a degree in Medicine from the Faculty of Medical Sciences of Minas Gerais. She completed a Medical Residency in Ophthalmology at the Holy House of Mercy in Belo Horizonte Eye Clinic by the CBO and AMB; a Fellowship in Clinical and Surgical Retina at the Holy House of Mercy Eye Clinic in Belo Horizonte; and a Fellowship in Ocular Oncology at University of Cincinnati – Ohio / USA. She is currently a member of the Clinical Body of the Ophthalmology Excellence Nucleus in Belo Horizonte and the preceptor of the medical residency of the Urgency and Retina department of the Holy House of Mercy Eye Clinic in Belo Horizonte. She also coordinates the Ocular Oncology (intraocular tumors) service of the Holy House of Mercy-BH Eye Clinic.


DOCTOR GEOPOLIANO CHAVES

Doctor Geopoliano Chaves obtained a bachelor’s degree in Biochemistry from the Federal University of Viçosa (MG) by studying the effects of polyphenols on enzymes in the model of kidneys of mice with atherosclerosis (2012) at the Biotechnology Laboratory of Dr. Nader Pourmand, UC Santa Cruz. He then went on to earn his Master’s degree from the University of São Paulo while studying Plasmodium falciparum, the parasite that causes malaria. His interest in how proteins are detected in biological samples motivated him to join the Pourmand Laboratory in 2014, participating in a project involving nanopipettes and next-generation sequencing. Since then, he has analyzed transcriptomic data in Huntingtons disease models, a neurodegenerative disorder. His dissertation work involves the use of nanopipettes to mitigate the nonspecific effects of the gene-editing technology by CRISPR / Cas9 and the underlying genetic analysis.


DOCTOR CLARISSA DE OLIVEIRA

Dr. Clarissa de Oliveira is a physician from the Federal University of Uberlândia, specializing in Anesthesiology. She has a postgraduate degree in nutritionology from the São Paulo Health School and graduated in Nutrology from ABRAN. She is also an active member of the AMBB, a fellow in Clinical Nutrition from BARM, a proud member of Oncology Society from the Albert Einstein Hospital and a coordinator of the Specialization Course in Integrative Medicine of UNIUBE


DRa. CLÁUDIA SOLMUCCI

Doctor hematologist, partner and owner of the Nucleus of Hematology/Oncology, coordinated for 22 years the Hematology service and the Blood Bank of the Biocor Hospital. Currently, Director-President of AbraC Brasil, Brazilian Association For Healing, association of research support.


DOCTOR CARLOS BARRIOS

Doctor Carlos Henrique Escosteguy Barrios holds a degree in Medicine from the Pontifical University of Rio Grande do Sul (1979) and is currently a professor at the Pontifical Catholic University of Rio Grande do Sul. He is also the Director of the Cancer Hospital of the Mãe de Deus Health System, and works as a physician at the São Lucas Hospital of PUCRS and as the director of the Latin American Clinical Research Group on Oncology (LACOG). He has a background in Internal Medicine, Hematology and Clinical Oncology, specializing breast cancer, lung cancer, kidney cancer and clinical research. Having participated in over 200 Clinical Research projects, he’s particularly interested in the development of Clinical Research Cooperative structures in Latin America.


DOCTOR FERNANDO SANTINI

A graduate from the Universidade Federal do Rio de Janeiro, Doctor Fernando Santini started his residency with the medic clinic at the Hospital das Clínicas da Universidade de São Paulo and soon afterwards did another residency specialized in hematology and hemotherapy at the very same hospital. In 2010, he worked at the Instituto do Câncer do Estado de São Paulo with their recently established lymphoma department, where he decided to dedicate himself to oncology. With that new goal in mind, in 2011 he started working at the Hospital Sírio-Libanês through a residency at their oncology clinic. He moved to New York in 2014 to specialize in thoracic oncology at the Memorial Sloan Kettering Cancer Center. He returned to Brazil in 2017 and is currently working at the oncology center at the Hospital Sírio-Libanês, where his main field is thoracic oncology.


DOCTOR MARCOS SANTOS

Doctor Marcos Daniel de Deus Santos graduated from UFES in 1994, where he completed a residency in clinical medicine in 1995 and 1996. He later completed another residency between the years of 1997 and 1998 at the Hospital Felicio Rocho in Belo Horizonte/MG, where he became a hematologist. He completed his Master’s degree from UFMG in 2003 and has been a university professor ever since, having lectured at the Faculty of Medical Sciences of MG, Emescam in Vitoria / ES. After passing a public examination in 2009, he became the assistant professor of the Department of Clínica Médica, UFES, where he holds the chair of Hematology. He is currently the Coordinator of Residence in Clinical Oncology and Coordinator of the Vila Velha Evangelical Hospital Hematology Department.